New R&D program for tyrosinemia type 1 (TT1) demonstrates how metabolism-targeted discovery extends from cancer into rare pediatric disease Faeth R&D is supported by MetabOS, a computational model ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an ...
New $25 million raise advances multi-node PI3K program; randomized phase 2 trial with Gynecologic Oncology Group Foundation now enrolling Faeth Therapeutics, a clinical-stage biotechnology company ...
Faeth Therapeutics announced a $47 million Series A funding round on Wednesday. The startup is studying specialized diets as a way to slow and cure cancer. It's one of the newest companies in the hot ...
Faeth Therapeutics is a clinical-stage biotechnology company integrating targeted therapies with precision nutrition interventions to exploit metabolic vulnerabilities in cancer. Founded by renowned ...
SAN FRANCISCO--(BUSINESS WIRE)--Faeth Therapeutics, a healthcare company developing machine learning-driven precision nutrition solutions and treatment regimens to enhance cancer therapy, today ...
Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary endpoint, supporting advancement to phase 3; combination extended mean ...
- Founding team includes the world’s leading cancer researchers and clinicians including Drs. Lew Cantley, Sid Mukherjee, Karen Vousden and others SAN FRANCISCO--(BUSINESS WIRE)--Faeth Therapeutics, a ...
New $25 million raise advances multi-node PI3K program; randomized phase 2 trial with Gynecologic Oncology Group Foundation now enrolling Faeth Therapeutics, a clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results